Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer

Future Medicinal Chemistry

Volumn 5, Issue 9, 2013, Pages 1023-1035

  Jiang, Quan ^a   Zheng, Shilong ^a   Wang, Guangdi ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BICYCLONONANE; CH 4986399; CYCLOFENIL; DEMETHYLARZOXIFENE; DROLOXIFENE; EXEMESTANE; FULVESTRANT; GW 7604; ICI 128 780; IDOXIFENE; LASOFOXIFENE; LETROZOLE; NSC 654077; OSPEMIFENE; PIPENDOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 1; ZK 253; ZK 703;

BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; DRUG TOLERABILITY; HORMONE RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TAMOXIFEN RESISTANT BREAST CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84878702605     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.63     Document Type: Review

References (73)

1. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801), 1461-1484 (2011).
2. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17(5), 1474-1474 (1999).
3. Fan P, Wang J, Santen Rj, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor a out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 67(3), 1352-1360 (2007).
4. Rao RD, Cobleigh MA. Adjuvant endocrine therapy for breast cancer. Oncology 26(6), 541-547 (2012).
5. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25(36), 5815-5824 (2007).
6. Jensen EV, Jordan VC. The estrogen receptor a model for molecular medicine. Clin. Cancer Res. 9(6), 1980-1989 (2003).
7. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 46(6), 883-908 (2003).
8. Hutcheson I, Knowlden J, Madden T-A, et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 81(1), 81-93 (2003).
9. Kurokawa H, Lenferink AEG, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60(20), 5887-5894 (2000).
10. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10(1), 331s-336s (2004).
11. Bachelot T, Bourgier C, Cropet C, et al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30(22), 2718-2724 (2012).
12. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012).
13. Finn R. Targeting Src in breast cancer. Ann. Oncol. 19(8), 1379-1386 (2008).
14. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer Res. 16(14), 3526-3532 (2010).
15. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor a positive breast cancer. Breast Cancer Res. Treat. 132(2), 391-409 (2012).
16. Rizzo P, Miao H, D'souza G, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68(13), 5226-5235 (2008).
17. Patel RR, Sengupta S, Kim HR, et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur. J. Cancer 46(9), 1537-1553 (2010).
18. Munster P, Thurn K, Thomas S, et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011).
19. Moreira PL, Custódio J, Moreno A, Oliveira CR, Santos MS. Tamoxifen and estradiol interact with the f lavin mononucleotide site of complex I leading to mitochondrial failure. J. Biol. Chem. 281(15), 10143-10152 (2006).
20. Johnston S, Gumbrell L, Evans T, et al. A cancer research (UK) randomized Phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother. Pharmacol. 53(4), 341-348 (2004).
21. Chang BY, Kim SA, Malla B, Kim SY. The effect of selective estrogen receptor modulators (SERMs) on the tamoxifen resistant breast cancer cells. Toxicol. Res. 27(2), 85-93 (2011).
22. Greenberger LM, Annable T, Collins KI, et al. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2 -piperidin-1-yl-ethoxy)-benzyl]-1H-indol- 5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and-resistant tumors and is devoid of uterotropic effects in mice and rats. Clin. Cancer Res. 7(10), 3166-3177 (2001).
23. Freddie CT, Larsen SS, Bartholomæussen M, Lykkesfeldt AE. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol. Cell. Endocrinol. 219(1), 27-36 (2004).
24. Baselga J, Llombart-Cussac A, Bellet M, et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann. Oncol. 14(9), 1383-1390 (2003).
25. Labrie F, Champagne P, Labrie C, et al. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J. Clin. Oncol. 22(5), 864-871 (2004).
26. Lacroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J. Natl Cancer Inst. 102(22), 1706-1715 (2010).
27. Schmidt C. Third-generation SERMs may face uphill battle. J. Natl Cancer Inst. 102(22), 1690-1692 (2010).
28. O'Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J. Natl Cancer Inst. 94(4), 274-283 (2002).
29. Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis. 24(1), 93-105 (2006).
30. Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin. Cancer Res. 6(6), 2260-2267 (2000).
31. Gao Z, Gao Z, Fields J, Boman B. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells. Anticancer Res. 22(3), 1379-1384 (2002).
32. Robertson J, Come S, Jones S, et al. Endocrine treatment options for advanced breast cancer -the role of fulvestrant. Eur. J. Cancer (Engl.) 41(3), 346 (2005).
33. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol. 27(27), 4530-4535 (2009).
34. Robertson JFR. Fulvestrant (Faslodex®) -how to make a good drug better. Oncologist 12(7), 774-784 (2007).
35. Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur. J. Cancer 44(3), 391-399 (2008).
36. Wittmann BM, Sherk A, Mcdonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67(19), 9549-9560 (2007).
37. Willson TM, Henke BR, Momtahen TM, et al. 3-[4-(1,2-diphenylbut-1-enyl) phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. 37(11), 1550-1552 (1994).
38. Kieser KJ, Kim DW, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J. Med. Chem. 53(8), 3320-3329 (2010).
39. Yoneya T, Taniguchi K, Nakamura R, et al. Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models. Anticancer Res. 30(3), 873-878 (2010).
40. Hoffmann J, Bohlmann R, Heinrich N, et al. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J. Natl Cancer Inst. 96(3), 210-218 (2004).
41. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348(24), 2431-2442 (2003).
42. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 83(6), 1142-1152 (1998).
43. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19(14), 3357-3366 (2001).
44. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16(2), 453-461 (1998).
45. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J. Clin. Oncol. 18(7), 1399-1411 (2000).
46. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32(3), 404-412 (1996).
47. Bertelli G. Sequencing of aromatase inhibitors. Br. J. Cancer 93, S6-S9 (2005).
48. Lønning Pe, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II Trial. J. Clin. Oncol. 18(11), 2234-2244 (2000).
49. Ghosh D, Lo J, Morton D, et al. Novel aromatase inhibitors by structure-guided design. J. Med. Chem. 55(19), 8464-8476 (2012).
50. Buzdar AU. TAS-108: a novel steroidal antiestrogen. Clin. Cancer Res. 11(2), 906s-908s (2005).
51. Yamamoto Y, Wada O, Takada I, et al. Both N-and C-terminal transactivation functions of DNA-bound ERa are blocked by a novel synthetic estrogen ligand. Biochem. Biophys. Res. Commun. 312(3), 656-662 (2003).
52. Saeki T, Noguchi S, Aogi K, Inaji H, Tabei T, Ikeda T. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Ann. Oncol. 20(5), 868-873 (2009).
53. Inaji H, Iwata H, Nakayama T, et al. Randomized Phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Cancer Sci. 103(9), 1708-1713 (2012).
54. Wang LH, Yang XY, Zhang X, et al. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat. Med. 10(1), 40-47 (2003).
55. Wang LH, Yang XY, Zhang X, et al. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10(6), 487-499 (2006).
56. Nichols M. The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle? Mol. Interv. 7(1), 13 (2007).
57. Koren J, Miyata Y, Kiray J, et al. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PLoS ONE 7(4), e35566 (2012).
58. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51, 227-238 (1998).
59. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21(10), 1973-1979 (2003).
60. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75(2), 305-316 (1977).
61. Hoskins JM, Carey LA, Mcleod HI. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
62. Bijl MJ, Van Schaik RHN, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118(1), 125-130 (2009).
63. Ahmad A, Shahabuddin S, Sheikh S, et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin. Pharmacol. Ther. 88(6), 814-817 (2010).
64. Mansel R, Goyal A, Nestour EI, Masini-Etévé V, O'Connell K. A Phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res. Treat. 106(3), 389-397 (2007).
65. Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G. Boron-based 4-hydroxytamoxifen bioisosteres for treatment of de novo tamoxifen resistant breast cancer. ACS Med. Chem. Lett. 3(5), 392-396 (2012).
66. Davoli A, Hocevar BA, Brown TL. Progression and treatment of HER2-positive breast cancer. Cancer Chemother. Pharmacol. 65(4), 611-623 (2010).
67. Wang X, Nakagawa-Goto K, Bastow KF, et al. Antitumor agents. 254. synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J. Med. Chem. 49(18), 5631-5634 (2006).
68. Dong Y, Shi Q, Pai H-C, et al. Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. J. Med. Chem. 53(5), 2299-2308 (2010).
69. Wang X, Bastow KF, Sun C-M, et al. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from salvia miltiorrhiza. J. Med. Chem. 47(23), 5816-5819 (2004).
70. WHO. The global burden of disease: 2004 update. www.who.int/healthinfo/ global-burden- disease/2004-report-update/en/index.html
71. National Cancer Institute at the NIH: breast cancer. www.cancer.gov/ cancertopics/types/breast
72. American Cancer Society: cancer facts and figures 2013. www.cancer.org/research/cancerfactsfigures/acspc-036845
73. National Cancer Institute: cancer advance in focus: breast cancer. www.cancer.gov/cancertopics/factsheet/cancer-advances-in-focus/breast